Specialized Care Significantly Extends Survival for Multiple Myeloma Patients
Table of Contents
A new study reveals that patients with newly diagnosed multiple myeloma (NDMM) experience dramatically improved outcomes – including a median overall survival of over 12 years – when treated at specialized clinics. The findings, published in the November issue of Haematologica, underscore the critical role of focused expertise in managing this challenging blood cancer.
A team led by Jonathan T. Moore, from the Berenson Cancer Center in West Hollywood, california, conducted a retrospective analysis of 175 patients initiating front-line treatment at their specialized clinic.The research highlights the potential for substantial gains in patient longevity through a concentrated approach to care.
Staging and Treatment Approaches
Researchers categorized patients using the Second Revised International Staging System, finding that 17.7% were stage I, 48.0% stage II, 12.0% stage III, and 22.3% had an unknown stage. The majority – 73.2% – received a combination of dexamethasone, bortezomib, and pegylated liposomal doxorubicin, often supplemented with lenalidomide. This aggressive, yet tailored, treatment strategy appears to be a key driver of the observed improvements.
Remarkable Survival Rates
The overall response rate to initial treatment was an impressive 71.4%. Patients experienced a median progression-free survival (PFS) of 22 months, and a remarkable median overall survival (OS) of 152 months – equivalent to 12 years and 8 months. long-term survival rates were also encouraging, with 95.8% surviving one year, 83.9% at three years, 77.2% at five years, and 59.9% at ten years.
Impact of Treatment Response
The study also investigated the correlation between treatment response and survival. While achieving at least a partial response to front-line therapy extended PFS (27 months versus 14 months for those who did not), it did not translate to a longer overall survival. Similarly, patients who achieved complete remission demonstrated longer PFS (42 months versus 18 months) but did not experience a statistically important improvement in OS. This suggests that while deep responses are beneficial for delaying disease progression, other factors contribute significantly to long-term survival.
“The highly individualized care multiple myeloma patients receive includes more treatment options than used anywhere in the world,” stated a senior author from the Berenson cancer Center. “These benefits have resulted in unprecedented outcomes for myeloma patients.”
Implications for Patient Care
The findings strongly suggest that consolidating care at specialized centers can significantly improve outcomes for individuals diagnosed with multiple myeloma.The study underscores the importance of access to comprehensive treatment protocols and a multidisciplinary team of experts.
Further research is needed to identify the specific components of specialized care that contribute most to improved survival. .
More facts: Jonathan T.Moore et al, Outcomes for unselected, newly diagnosed multiple myeloma patients, Haematologica (2025). DOI: 10.3324/haematol.2025.287458
© 2025 HealthDay.All rights reserved.
citation: Treatment of multiple myeloma at specialized clinic tied to improved survival (2025,November 24) retrieved 24 November 2025 from https://medicalxpress.com/news/2025-11-treatment-multiple-myeloma-specialized-clinic.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part might potentially be reproduced without the written permission.The content is provided for information purposes only.
